Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

This study has been terminated.
(Manufacturer stopped drug development)
Novartis Pharmaceuticals
Information provided by (Responsible Party):
David Rizzieri, MD, Duke University Medical Center Identifier:
First received: August 1, 2007
Last updated: November 19, 2014
Last verified: November 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2010
  Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 7, 2012